Earnings Call · Q2 FY2025·2025-08-08

Q2 25EPS +33.33%·Rev n/aQ1 25EPS -7.69%·Rev n/aQ4 24EPS -21.01%·Rev n/aQ3 24EPS +100.00%*·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Louise Wilkie — Head of Investor Relations and Corporate Communications

Alexander D. Macrae — Chief Executive Officer

Nathalie Dubois-Stringfellow — Chief Development Officer

−5.3%1d on move date−6.1% vs SPY3d+7.2%5d+11.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access